Project

Go Back to Project List
#4189 : Transcriptional response of M. tuberculosis to candidate drug Macozinone.
Topics: Transcriptomics (Illumina)
Origin: IP
Project type: Development

Name of Applicant: Roland Brosch
Date of application: 06-07-2020
Unit: Integrated Mycobacterial Pathogenomics
Location: Guerin
Phone: 0140613754
@ Mail: roland.brosch@pasteur.fr
Collaboration with:BELGIUM,FRANCE (LILLE)

Project context and summary:

Despite decades of efforts and progress in the field, Tuberculosis (TB) remains one of the world’s most deadly infectious diseases. A major concern in the fight against TB, is the increasing worldwide spread of multidrug resistant Mycobacterium tuberculosis (MDR-TB) strains, lowering treatment success rates drastically. Therefore, a main goal in TB research is the development of new anti-TB drugs. One of these new potential candidates, is the piperazine-containing benzothiazinone Macozinone (previously PBTZ-169). This bactericidal drug, which is currently in clinical Phase I/II studies, targets the essential flavoprotein DprE1.
In this project will investigate the effect of Macozinone on M. tuberculosis on a transcriptional level. Therefore, differential expression analyses will be performed for two pan-susceptible M. tuberculosis strains incubated with bactericidal concentrations of this drug.


Related team publications:
o Van den Bossche A, Varet H, Sury A, Sismeiro O, Legendre R, Coppee JY, Mathys V, and Ceyssens PJ. (2019) Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid. Tuberculosis, 117: 18-23. doi: 10.1016/j.tube.2019.05.002
Service Delivery
Manager: marc.monot@pasteur.fr
Status: Closed


Go Back to Project List